Glucose-stimulated insulin secretion [GSIS] involves interplay between small G-proteins and their regulatory factors. Herein, we tested the hypothesis that Arf nucleotide binding site opener [ARNO], a guanine nucleotide exchange factor [GEF] for the small G-protein Arf6, mediates the functional activation of Arf6, and that ARNO/Arf6 signaling axis, in turn, controls the activation of Cdc42 and Rac1, which have been implicated in GSIS. Molecular biological [i.e., expression of inactive mutants or siRNA] and pharmacological approaches were employed to assess the roles for ARNO/Arf6 signaling pathway in insulin secretion in normal rat islets and INS 832/13 cells. Degrees of activation of Arf6 and Cdc42/Rac1 were quantitated by GST-GGA3 and PAK-1 kinase pull-down assays, respectively. ARNO is expressed in INS 832/13 cells, rat islets and human islets. Expression of inactive mutants of Arf6 [Arf6-T27N] or ARNO [ARNO-E156K] or siRNA-ARNO markedly reduced GSIS in isolated β-cells. secinH3, a selective inhibitor of ARNO/Arf6 signaling axis, also inhibited GSIS in INS 832/13 cells and rat islets. Stimulatory concentrations of glucose promoted Arf6 activation, which was inhibited by secinH3 or siRNA-ARNO, suggesting that ARNO/Arf6 signaling cascade is necessary for GSIS. secinH3 or siRNA-ARNO also inhibited glucose-induced activation of Cdc42 and Rac1 suggesting that ARNO/Arf6 might be upstream to Cdc42 and Rac1 activation steps, which are necessary for GSIS. Lastly, coimmunoprecipitation and confocal microscopic studies suggested increased association between Arf6 and ARNO in glucose-stimulated β-cells. These findings provide the first evidence to implicate ARNO in the sequential activation of Arf6, Cdc42 and Rac1 culminating in GSIS.
Introduction
It is widely accepted that small G-proteins regulate various cellular functions including proliferation, survival and demise. At least four major classes of small G-proteins have been identified in the pancreatic β-cell. These include the Ras, Rho, Rab and ADP-ribosylation factor [Arf] family of G-proteins [1] , of which Arf family of G-proteins is less studied in the islet. Though originally identified as an ADP-ribosylator for cholera toxin, Arf has gained much importance as a critical modulator of membrane traffic in eukaryotic cells. Among the six members of the Arf family, Arf6 is a well documented protein for its positive modulatory roles in multiple cell types including regulation of various effector proteins [e.g., phospholipase-D; PLD] and trafficking of secretory granules to the plasma membrane for exocytosis [2] . Regazzi and coworkers first described localization and regulation of Arfs in insulin-secreting RINm5f cells [3, 4] . More recently, Lawrence and Birnbaum have demonstrated regulatory roles for Arf6 in insulin secretion mediated by glucose, GTPγS and membrane depolarization. They further demonstrated that Arf6 regulates insulin secretion by maintaining plasma membrane phosphatidylinositol 4, 5-biphosphate [PIP 2 ; 5] . Existing evidence also supports a potential role for PLD in physiological insulin secretion [6, 7, 8] .
Arf6 cycles between the GDP-bound [inactive] and GTP-bound [active] configurations; which are tightly regulated by two distinct classes of regulatory factors namely the GTPase activating proteins [GAP] and the GTP/GDP exchange factors [GEF; 9, 10] . GAPs inactivate Arf6 by promoting its conversion to the inactive GDP-bound form, while GEFs facilitate its activation. The GEF activity is a rate-defining step and involves coordination of multiple intracellular signals. In this context, many GEFs with distinct size and structure have been identified for Arf6 [11] [12] [13] [14] [15] [16] . However, in the majority of the signaling events, only one member belonging to the cytohesin family has been closely linked to activate Arf6 [13, 14, 17, 18] . Recently, Hafner et al., reported a small molecule inhibitor, secinH3, which selectively blocks ARNO-mediated activation of Arf6 [19] . Previous studies have utilized secinH3 to determine the regulatory roles for ARNO/Arf6 signaling in cellular signal transduction [20, 21] .
In an attempt to identify precise regulatory mechanisms involved in glucose-mediated activation of Rac1 and insulin secretion, we first proposed [22] and subsequently confirmed experimentally [23] that certain biologically-active lipid second messengers [e.g., PA, PIP 2 ] promote dissociation of Rac1 from Rac1/GDI complex to facilitate activation of Rac1 in rodent islets and clonal β-cells. Therein, we also proposed that Arf6 could represent one of the upstream regulators of Rac1 activation by generating relevant lipid second messengers via phospholipase activation to dissociate the Rac1/GDI complex [22, 23] . Studies from Thurmond's laboratory have demonstrated the requirement of Cdc42, a Rho family GTPase in the Rac1 activation process for actin remodeling and insulin exocytosis [24, 25] . The current study is undertaken to test the hypothesis that ARNO mediates sequential activation of Arf6, Cdc42 and Rac1 leading to GSIS. Using molecular biological and pharmacological approaches we provide below the first evidence to in support of this hypothesis in normal rodent islets and insulin-secreting INS 832/13 cells. 
Materials and Methods

Materials
Insulin-secreting INS 832/13 cells, rat islets and human islets
INS 832/13 cells were kindly provided by Dr. Chris Newgard (Duke University Medical Center, Durham, NC). The cells were cultured in RPMI 1640 medium containing 10% heatinactivated fetal bovine serum supplemented with 100 IU/ml penicillin and 100 IU/ml streptomycin, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol, 11 mM glucose, and 10 mM HEPES (pH 7.4). Islets were isolated from pancreas of male Sprague-Dawley rats (Harlan Laboratories, Oxford, MI), using collagenase digestion and a ficoll gradient as we described previously [22] . All experiments were reviewed and approved by the Wayne State University Institutional Animal Care and Use Committee. Human pancreatic islet lysates were kindly provided by Dr. Karl Olson [Michigan State University, Lansing, MI].
Hydrophilic and hydrophobic phase partitioning method using Triton X-114
Total hydrophobic and hydrophilic phases of lysates derived from INS 832/13 cells and pancreatic islets were separated using Triton X-114 according to method described earlier by us [22] . Briefly, about 400 μg of cell [INS 832/13 cell or islet] homogenate protein, prepared in 400 μl of buffer (20 mM Tris-HCl, pH 7.5, 0.5 mM EGTA, 2 mM MgCl 2 , 10 μg/ml leupeptin, and 2 μg/ml aprotinin), supplemented with 1 % (w/v) Triton X-114 was overlaid on 400 μl sucrose cushion 6 % (w/v) prepared in 20 mM Tris-HCl buffer (pH 7.4) containing 0.06 % (w/v) Triton X-114. Following brief incubation at 30 °C, samples were centrifuged at 300 × g for 3 min and the aqueous phase was mixed with 0.5 % (w/v) fresh Triton X-114 at 4 °C. Following dissolution, the mixture was again overlaid on the same sucrose cushion, incubated for 3 min at 30 °C and centrifuged at 300 × g for 3 min. The lower hydrophobic phase was diluted to a final volume of 400 μl with homogenization buffer, while the aqueous phase was transferred into a separate tube supplemented with 2 % fresh Triton X-114, incubated for 3 min at 30 °C, and centrifuged at 300 × g without sucrose cushion. The supernatant obtained thereof served as total hydrophilic phase. The relative abundance of ARNO in hydrophilic and hydrophobic phases were determined by Western blotting. 
Transfection of Arf6 or ARNO mutants and siRNAs
INS
Insulin release studies
Arf6 or ARNO mutant or siRNA-transfected or secinH3 inhibitor-treated cells were cultured overnight in low serum and low glucose containing medium and then stimulated either with high glucose, KCl or arginine in Krebs-Ringer bicarbonate buffer [KRB, pH 7.4] for different time intervals as indicated in the text. In studies involving KCl-induced insulin secretion, we noticed that INS 832/13 cells were not responsive to 40 mM KCl in releasing insulin. However, higher KCl concentrations [60 mM] were found to elicit robust insulin release. Therefore, in KCl-stimulated insulin secretion studies, cells were incubated with 60 mM KCl in an osmolarity-balanced KRB medium [5] . For arginine [L-Arg]-stimulated insulin release, a stock solution was prepared in Tris.HCl [pH 7.4] , and diluted to desired concentration with KRB. The insulin released into the medium was quantitated by ELISA [22] .
Quantitation of Arf6.GTP in pancreatic β-cells
Active Arf6 was quantitated by a pull-down assay. Briefly, the incubation medium was aspirated and cells were washed with ice-cold PBS. Cells were lysed with 500 μl lysis buffer and the lysate was clarified by centrifugation at 16,000 × g at 4 °C for 15 min and incubated ∼400 μg protein with 100 μl of glutathione resin and 100 μg of GST-GGA3-PBD beads at 4°C for 1 hr with gentle rocking, following which the reaction mixture was spun at 6,000 × g for 30 sec. The GST-tagged beads were washed [3×] and proteins were separated by SDS-PAGE and activated Arf6 was identified by Western blotting.
Quantitation of Cdc42 and Rac1 activation
Relative degree of activated Cdc42 and Rac1 [i.e., GTP-bound form] were determined by p21-activated kinase-p21-binding domain pull-down assay as described in [22] . Briefly, INS 832/13 cells treated with either diluent or secinH3 [50 μM] or cells were either mocktransfected or transfected with ARNO-siRNA were cultured overnight in low serum-low glucose media. Cells were stimulated with either low [2.5 mM] or high [20 mM] glucose for 3 or 30 min at 37 °C in the continued presence of either diluent or secinH3 with respect to inhibitor studies. The GTP-bound forms of Cdc42 and Rac1 in the pull-down samples were quantitated by Western blotting and densitometry.
Co-immunoprecipitation studies
Immunoprecipitation studies were performed using the Classic Co-IP kit as suggested by the manufacturer [26] . Briefly, β-cell lysates [500 μg protein] were incubated with anti-ARNO for 2 hr at 4 °C followed by incubation with agarose resin for an additional 1 hr at 4 °C. Beads were washed; eluted using sample buffer and proteins were resolved by SDS page to quantify Arf6.
Immunofluorescence studies
INS 832/13 cells were plated onto coverslips and incubated with [2.5 or 20 mM] glucose for 30 min at 37 °C followed by washing in PBS and fixed with 4% paraformaldehyde solution for 15 min at room temperature. They were then permeabilized with 0.2% Triton X-100 for 15 min at room temperature. After blocking with 1% BSA for 1 hr, the cells were further incubated with primary antibodies Arf6 [1:150] 
Statistical analyses
The statistical significance of the difference between the experimental conditions was determined by Student's t test unless mentioned otherwise. p values < 0.05 were considered significant.
Results
Distribution of ARNO in pancreatic β cells
Data shown in Figure 1A indicated that ARNO is expressed in normal rat islets, human islets and INS 832/13 cells. The relative abundance of ARNO in the total hydrophilic and hydrophobic compartments [isolated from cell lysates using Triton X-114 phase separation protocol; see Methods] indicated that ARNO remains associated with the hydrophilic compartment [ Figure 1B ]. Figure 2C showed a marked reduction in GSIS in cells expressing Arf6-T27N. Likewise, overexpression of ARNO-E156K, a mutant lacking the GEF function, significantly inhibited GSIS in these cells [ Figure 2D ]. Together, these data suggested key roles for Arf6 and ARNO in signaling events leading to GSIS. Next, we verified if knockdown of endogenous Arf6 and ARNO by using siRNA affects insulin secretion elicited by high glucose. We observed 50-60% reduction in the expression of Arf6 or ARNO by Western blotting analysis [ Figure 2B ]. Under these conditions, GSIS was significantly inhibited in Arf6-and ARNO-knocked-down cells [ Figure 2E and 2F]. Together, data in Figure 2 [Panels C-F] implicated Arf6/ARNO signaling axis in GSIS.
Molecular biological inhibition of
In the next series of studies, we determined potential roles of Arf6 or ARNO in insulin secretion elicited by a membrane-depolarizing concentration of KCl or arginine. To address this, INS 832/13 cells were transfected with either siRNA-Arf6 or siRNA-ARNO, and insulin secretion in the presence of KCl [60 mM; Figure 2G ] or arginine [20 mM; Figure 2H and 2I] was quantitated. Data depicted in Figure 2 [panels G -I] demonstrated that insulin secretion elicited by KCl or arginine was inhibited in cells in which the endogenous Arf6 or ARNO was knocked-down. Together, data described in Figure 2 implicate regulatory roles for ARNO/Arf6 in insulin secretion elicited by a variety of secretagogues.
Glucose activates Arf6 in pancreatic β-cells
To further understand the role of Arf6 in stimulus-coupled secretion, we next examined whether insulinotropic concentrations of glucose activates Arf6 in the β-cell. This was accomplished by using a recently developed GST-GGA3 pull-down assay, which utilizes GGA proteins to capture activated forms of Arf6 by interacting with the Arf-binding domain [27] . Efficiency and specificity of the activation assay was confirmed by the ability of GTPγS to stimulate Arf6 activation in broken cell preparations [additional data not shown]. 
siRNA-mediated knockdown of ARNO or pharmacological inhibition of ARNO/Arf6 signaling results in attenuated glucose-induced activation of Arf6
The conversion of the GDP-bound inactive forms of G-proteins to their GTP-bound active state is mediated by GEFs. The above data prompted us to investigate if ARNO represents one of the GEFs for glucose-mediated activation of Arf6. This was verified by two complementary methods. In the first, glucose-induced activation of Arf6 was examined in cells in which ARNO expression was reduced by siRNA-ARNO. Data in Figure 4A and 4B indicated complete inhibition of glucose-induced activation of Arf6 under these conditions. This was further verified by a second approach involving pharmacological inhibition of ARNO/Arf6 signaling by secinH3 [19] [20] [21] . Data in Figure 4C and 4D suggested a complete inhibition of glucose-induced activation of Arf6 by secinH3. Taken together, these data indicate that glucose-induced activation of Arf6 requires the intermediacy of ARNO.
SecinH3 markedly attenuates GSIS in INS 832/13 cells and rat islets
As a logical extension to the above studies, we next investigated potential impact of pharmacological inhibition of ARNO on GSIS in INS 832/13 cells and normal rat islets. Data in Figure 5 demonstrated complete inhibition of GSIS by secinH3 in INS 832/13 cells [ Figure 5A ] and normal rat islets [ Figure 5B ]. Under these conditions secinH3 failed to increase basal secretion in either INS 832/13 cells or rat islets [ Figure 5A and 5B]. It should be noted that inhibitory effects of secinH3 on Arf6 activation [ Figure 4 ] or GSIS [ Figure 5 ] were not due to its cytotoxic effects since we noticed no significant effects of this inhibitor on the metabolic cell viability of β-cells under these conditions [not shown]. Together, these pharmacological data confirm the above molecular biological data to support our hypothesis that ARNO/Arf6 signaling cascade plays a positive modulatory role in GSIS.
siRNA-mediated knockdown of ARNO or pharmacological inhibition of ARNO leads to marked reduction in glucose-induced activation of Rac1 and Cdc42
Several recent studies, including our own, have implicated Rho subfamily of small Gproteins [e.g., Cdc42 and Rac1] in cytoskeletal remodeling leading to the translocation of insulin-laden secretory granules to the plasma membrane for fusion and exocytotic secretion of insulin [28, 29] . In this context, recent evidence appears to suggest a significant cross-talk between ARNO/Arf6 and Rac1 in the regulation of cell function in multiple cell types [30] [31] [32] [33] [34] [35] . Therefore, we asked if ARNO/Arf6 signaling axis regulates glucose-induced Rac1 activation in the pancreatic β-cell. We addressed this question by quantitating glucoseinduced Rac1 activation in INS 832/13 cells in which ARNO function is compromised via pharmacological [e.g., secinH3] or molecular biological [e.g., siRNA-ARNO] approaches. As expected, we noticed a significant Rac1 activation in control cells exposed to glucose [ Figure 6A ]. Interestingly, siRNA-mediated knockdown of ARNO increased Rac1 activation under basal glucose conditions. However, glucose-induced activation of Rac1 was completely inhibited in ARNO-depleted β-cells [ Figure 6A ]. Likewise, pharmacological inhibition of ARNO/Arf6 signaling axis with secinH3 abolished glucose-induced activation in these cells [ Figure 6B ] suggesting that ARNO/Arf6 signaling step might be upstream to the Rac1 activation step in the cascade of events leading to GSIS. These data, which are compatible with our original proposal [22] also fit into the time-frame for glucose-induced activation of these proteins. We noticed in this study that Arf6 activation is seen as early as 1 min while glucose-induced activation of Rac1 is maximal at 15-20 min [28, 29] . Along these lines, earlier studies from our laboratory have suggested that the carboxylmethylation of Cdc42 is stimulated by glucose within 1 min of exposure [36] . More recent and comprehensive investigations by Thurmond's group [24, 25] have reported glucose-induced activation of Cdc42 within 3 min of exposure. They also demonstrated that Cdc42 activation is upstream to Rac1 activation in the cascade of events leading to GSIS [25] . Therefore, we examined if inhibition of ARNO/Arf6 signaling step affects Cdc42 activation. Our findings suggested ∼50% inhibition of glucose-induced activation of Cdc42 in INS 832/13 cells following inhibition of ARNO/Arf6 by secinH3 [ Figure 6C ]. Together, our findings are suggestive of sequential activation of Arf6, Cdc42 and Rac1 by ARNO in glucose-stimulated β-cell culminating in insulin secretion.
It should be noted that recent investigations from our laboratory have described the roles for Tiam 1, a GEF for Rac1 in GSIS. For example, we have shown that siRNA-mediated knockdown of Tiam1 or pharmacological inhibition of Tiam1/Rac1 signaling axis [e.g., NSC23766] markedly attenuated GSIS in INS 832/13 cells [37] . Along these lines, Western blot data indicated expression of Dbl, a known GEF for Cdc42 [38] , in INS 832/13 cells, normal rat islets and human islets [ Figure 6D ]. Together, these data are suggestive expression of at least three GEFs [i.e., ARNO, Tiam1 and Dbl] in the islet β-cell. Potential cross talk between these GEFs, if any, in the context of GSIS, remains to be verified.
Glucose promotes association between Arf6 and ARNO in pancreatic β-cells
In the last series of studies we utilized co-immunoprecipitation and immunofluorescence approaches to further determine if exposure of isolated β-cells to an insulinotropic concentration of glucose promotes association between Arf6 and ARNO. Data shown in Figure 7A indicate detectable levels of Arf6 in ARNO immunoprecipitates suggesting that these two proteins stay complexed under basal conditions. Moreover, incubation of these cells with stimulatory glucose resulted in a significant increase [∼2-fold] in the amount of Arf6 in the ARNO immunoprecipitates [ Figure 7B ]. Together, these data suggest that glucose promotes physical association between ARNO and Arf6 in insulin-secreting cells. We verified these findings via a complementary immunofluorescence approach. Data in Figure 7C 
Discussion
It is widely accepted that the Arf family of G-proteins play a key regulatory role in membrane trafficking [9] . Among these, Arf6 is well studied and has been shown to regulate several cellular events including cell motility, vesicular transport, and cortical actin rearrangements [17, 32, 39] . In addition, Arf6 has been shown to activate several G-proteins and enzymes of lipid metabolism including PLD to generate fusogenic lipids such as PA and PIP 2 [40, 41] . Such experimental evidence led to the postulation that Arf6 might represent one of the G-proteins whose activation may be necessary for the trafficking of secretory vesicles to the plasma membrane and fusion to lease their contents into the circulation.
The functions of Arf6 are regulated by factors such as GEFs. Despite compelling evidence in many cell types, little is known with regard to regulatory factors for Arf6 in β-cells. Therefore, in the current study, we tested the hypothesis that ARNO mediates the functional activation of Arf6, and that the ARNO/Arf6 signaling cascade, in turn, controls the activation of downstream regulatory proteins including Cdc42 and Rac1 leading to GSIS. In the present study we demonstrated that ARNO might subserve the function of a GEF for Arf6 in the islet β-cell. Regazzi et al first reported [3, 4] that incubation of permeabilized RINm5F cells with nonhydrolyzable analogs of GTP resulted in a significant redistribution of otherwise cytosolic Arfs to the Golgi and plasma membrane compartments. Based on these and insulin secretion data, they concluded that Arf is subjected to cycling between the membrane and soluble compartments and this cycling is governed by regulatory factors to mediate insulin secretion in clonal β-cells. And more recently Lawrence and Birnbaum demonstrated regulatory roles for Arf6 in insulin secretion from MIN6 cells [5] . Using adenoviral expression protocols involving the wildtype, dominant negative and constitutively active Arf6 mutants, these investigators provided compelling evidence to implicate regulatory roles for Arf6 in glucose-, KCl-and GTPγS-induced insulin secretion. Along these lines, at least two other recent studies have verified roles for Arf6 in islet function and insulin secretion. Grodnitzky et al have demonstrated a role for EFA6A, another GEF for Arf6 in somatostatin-mediated activation of PLD in clonal β [HIT-T15] cells. Interestingly, however, this pathway appears to be distinct from glucose-mediated effects in INS 832/13 cells and normal rat islets [current study] since overexpression of inactive ARNO mutant [E156K] failed to affect somatostatin-induced PLD activation [42] . More recent findings by Ma and coworkers further implicated Arf6 in glucose-induced PLD activation in MIN6N8 cells, which suggested binding of Arf6 to PLD. Furthermore, brefeldin A, a known inhibitor of Arf6, decreased glucose-induced PLD activity and insulin secretion [43] .
What then is the potential connection between glucose-induced ARNO/Arf6 signaling cascade and Rac1 activation that we have demonstrated in the current study? We proposed earlier [22] that Rac1 activation might be downstream to Arf6 in the signaling events leading to GSIS. More recently we have provided further evidence to suggest that biologically-active, fusogenic lipids regulate Rac1 signaling in the β-cell [23] . For example, using lysates derived from normal rat islets and INS 832/13 cells we have demonstrated that these lipids promote the dissociation of Rac1/GDI complex, which is necessary for the membrane translocation and activation of Rac1 [23] . Earlier observations also demonstrated potential involvement of PLD activation in the signaling mechanisms leading to GSIS [6, 7, [44] [45] [46] . Therefore, it is reasonable to speculate that glucose-induced Arf6-mediated activation of PLD1 [43] results in biologically active, fusogenic lipids, which, in turn, facilitate the dissociation of Rac1/GDI complex and leading to the translocation, membrane association and activation of Rac1 culminating in the cytoskeletal remodeling and fusion of granules with the plasma membrane. This remains to be verified experimentally. in GSIS [25] . Based on these findings, we propose that GSIS involves sequential activation of ARNO-mediated stimulation of Arf6, Cdc42 and Rac1 as shown below.
However, it remains to be verified if Cdc42 activation mechanism by ARNO/Arf6 also involves the dissociation of Cdc42/GDI complexes by biologically-active lipids as in the case of Rac1 [23] . Further, it is likely that ARNO/Arf6-mediated Cdc42 activation in the β-cell might involve a mechanism similar to the one described in MCF7 cells by Dubois et al [47] . These investigators have demonstrated that active Arf proteins bind to Cdc42. GTPase activating protein thereby preventing its GAP function and retain Cdc42 in the GTP-bound active conformation. Such a possibility remains to be verified for Arf6 in the islet.
Lastly, our current studies identify ARNO as one of the GEFs for glucose-induced activation of Arf6. The list of G-protein regulatory factors involved in GSIS continues to grow. Along these lines, we have identified Tiam1 as one of the GEFs for Rac1 [37] . Rho-GDI appears to subserve the roles of GDI for Cdc42 and Rac1 [29] . The above described Western blot data are suggestive of localization of Dbl, a known GEF for Cdc42, in INS 832/13 cells, normal rat islets and human islets. Studies are underway to determine potential cross-talk between various GEFs and their corresponding G-proteins in the cascade of events leading to insulin secretion.
In conclusion, based on the existing experimental data including those described herein, we propose a mechanism [ Figure 8 ] involved in GSIS in pancreatic β-cells involving ARNO/ Arf6 signaling steps. We propose that GSIS involves ARNO-mediated conversion of GDPArf6 [inactive] to GTP-Arf6 [active]. We verified this by over-expression of dominant negative mutants of ARNO and Arf6 as well as siRNA-mediated knockdown of these proteins in pancreatic β-cells. This postulation was further supported by our findings of pharmacological inhibition of glucose-induced ARNO-mediated activation of Arf6 by secinH3. Based on the data described herein and our previously published data [22, 23] , it is likely that glucose metabolic events lead to the activation of endogenous phospholipases, including PLD [44, 45] and the subsequent generation of biologically-active lipid second messengers [e.g., PA and PIP 2 ], which, in turn, facilitate the dissociation of Rac1/GDI complex for attaining the GTP-bound active conformation [23] . Potential involvement of ARNO/Arf6-mediated activation of Cdc42 and Rac1 via PLD remains to be verified. Finally, as we demonstrated previously [48] , it is also likely that biologically-active lipids could exert direct effects on the functional activation of specific GTPases by increasing their GTP binding function and decreasing their GTPase activities thereby retaining putative Gproteins in their GTP-bound active conformation [29] .
Lastly, it may be germane to pint out that data described above implicated regulatory roles for ARNO/Arf6 signaling axis in insulin secretion elicited by KCl. Our current observations are compatible with studies of Lawrence and Birnbaum implicating a role for Arf6 in KClinduced insulin secretion [5] . However, it remains to be seen if ARNO/Arf6 signaling cascade regulates additional pathways which are independent of Cdc42/Rac1 activation in insulin-secreting cells. Such an examination is necessary since recent studies have clearly implicated non-regulatory roles for Cdc42/Rac1 signaling pathways in KCl-induced insulin secretion [28,29 and references therein] . To the best of our knowledge, very little is known with regard to potential involvement of small G-proteins [e.g., Rac1] in insulin secretion facilitated by amino acids, such as arginine. These aspects, which are not included in the current model [ Figure 8 ], are being investigated in our laboratory currently. .GTP] was determined by PAK-PBD pull down assay. Total Cdc42 from cell lysates was used as the loading control. Data were densitometrically analyzed and is expressed as fold change in Cdc42.GTP over basal and are mean ± SEM of three independent experiments yielding similar results. * and ** represents p<0.05 vs. low glucose without secinH3 and # p < 0.05 vs. high glucose without secinH3. Panel D: Lysates from rat islets, human islets and INS 832/13 cells were separated by SDS-PAGE and probed for Dbl by Western blotting. Based on the data described herein and our previously published data [22, 23] , we propose a model for potential involvement of ARNO as a GEF for Arf6 in promoting GSIS in pancreatic β-cells. We propose that glucose activates islet endogenous ARNO to facilitate the conversition of inactive GDP-bound Arf6 to its GTP-bound biologically active conformation. Essential nature for ARNO in this signaling cascade was demonstrated via the use of molecular biological [E156 mutant and siRNA-ARNO] and pharmacological approaches [e.g., secinH3]. A role for Arf6 in GSIS was confirmed via molecular biological [i.e., Arf6-T27N mutant and siRNA-Arf6] approaches. These data confirm the original observations of Lawrence and Birnbaum [5] . We propose that the activation of ARNO/Arf6 signaling pathway leads to the activation of PLD [43] leading to the generation of fusigenic lipids [e.g., PA], which in turn, promote dissociation of Rac1/GDI complexes leading to the activation and membrane association of Rac1 [22, 23] . Our time course studies also suggest that ARNO-mediated activation of Cdc42 [within 1 min] is unstream to Rac1 activation [15-20 min] together suggesting that ARNO facilitates sequential activation of Arf6, Cdc42 and Rac1 to promote insulin secretion. Potential mechanisms underlying Arf6 mediated activation of Cdc42 remain to be determined. It might include dissociation of Cdc42/GDI complex by biologically-active lipids as in the case of Rac1 [21, 22] or inhibition of GAP activity specific for Cdc42 by ARNO/Arf6 signaling pathway [see Discussion]. These aspects are being investigated in our laboratory currently.
